ERBB2 and breast cancer: Compared with Trastuzumab, T-DM1 significantly improved invasive disease-free survival in patients with HER2+ early breast cancer; distant recurrence in the T-DM1 group was 10.5%, compared to 15.9% in the trastuzumab group [70].